ONCURA Signs Contract With The London Clinic To Support New
Prostate Cancer Service
30 August 2007
ONCURA, a leading provider of brachytherapy products, has been
awarded the contract with The London Clinic – one of the UK’s most
established independent hospitals – to provide radioactive seeds
for their new low dose rate (LDR) brachytherapy service for the
treatment of prostate cancer, one of the commonest forms of cancer
in men.
Professors Stephen Langley and Roger Kirby, consultant
urologists at The London Clinic, will head up this new service.
LDR brachytherapy is a proven1, cost-effective treatment for
early, localised prostate cancer2. It is minimally invasive and
involves implanting tiny radioactive seeds through fine needles
into the prostate to destroy the cancer cells. Its side effect
profile offers patients less risk of impotence and incontinence
after treatment, compared to other treatment options3. The
procedure is carried out under general anaesthetic and most
patients go home the following day.
Explains Saheed Rashid, Marketing Director, Oncura, “We are
delighted to be working in partnership with The London Clinic to
provide this service. LDR brachytherapy is an effective and
convenient therapy for treating localised prostate cancer and an
important option for men diagnosed with the disease.”
“This new service will expand our existing portfolio of
specialist services for men not just in London, but across the UK
as well as abroad”, added Malcolm Miller, Chief Executive of The
London Clinic.